Newly Diagnosed Myeloma in 2020
Philippe Moreau1, Cyrille Touzeau1, Ravi Vij2
1Department of Hematology, University Hospital, Nantes, France.
Summary
Recent advances in multiple myeloma (MM) treatment offer improved survival and tolerance. Selecting optimal frontline therapies, including autologous stem cell transplantation (ASCT) and novel combinations, remains crucial for newly diagnosed patients.
Area of Science:
- Hematology
- Oncology
- Clinical Therapeutics
Background:
- Multiple myeloma (MM) treatment has seen significant advancements with new agents and combinations.
- Improved survival and tolerance are observed in newly diagnosed MM patients.
- The expanding treatment landscape presents challenges in personalized therapy selection.
Observation:
- The increasing number of treatment options presents a challenge in tailoring therapy to individual patient needs.
- Autologous stem cell transplantation (ASCT) remains a standard for eligible younger patients, with triplet combinations forming the induction therapy backbone.
- For elderly patients ineligible for ASCT, lenalidomide-based therapies and anti-CD38 antibody combinations are emerging as frontline strategies.
Findings:
- A decade of clinical trials has identified key endpoints and toxicities for frontline MM treatment in both younger and older adults.
- Predictive tools can aid in selecting regimens for older adults by assessing physiologic age and treatment tolerance.
- Post-transplant strategies like consolidation and maintenance therapy aim to deepen responses and prolong progression-free survival.
Implications:
- Optimizing frontline treatment selection for multiple myeloma is crucial for maximizing patient benefits.
- Personalized therapeutic approaches, potentially guided by predictive tools, are essential for diverse patient populations.
- Continued research into clinical endpoints and toxicities will refine treatment strategies for newly diagnosed multiple myeloma.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
01:20Myasthenia Gravis: Overview and Treatment
2.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.6K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:49Cancer Therapies
9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
02:07Tumor Progression
7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
01:15Myasthenia Gravis: Diagnostic Tests
1.8K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.8K